GlassScriptPhysician profile
Frances S Long
NPI 1194778316
$2,220.62
in general payments reported to CMS, 2019-2025
22 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.30 · 2020: $15.76 · 2022: $202 · 2023: $519 · 2024: $737 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $376.08 | 2022-2025 | |
| Lilly USA, LLC | $247.82 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Currax Pharmaceuticals LLC | $194.91 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Novo Nordisk INC | $188.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $181.12 | 2019-2025 | |
| Abbott Laboratories | $178.23 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $124.92 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Coloplast Corp | $110.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $101.04 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $85.81 | 2023-2025 | Lagevrio, Belsomra, Gardasil 9 |
| Amgen INC. | $85.16 | 2024-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $73.18 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $66.69 | 2023-2024 | Veozah |
| Medtronic, INC. | $52.52 | 2022-2024 | Interstim |
| Ucb, INC. | $23.34 | 2024 | Nayzilam |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $23.13 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.72 | 2024 | Xifaxan |
| Dexcom, INC. | $18.24 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.02 | 2025 | Jardiance |
| Beone Medicines USA, INC. | $17.54 | 2025 | Tevimbra |
| Becton, Dickinson and Company | $17.08 | 2024 | Venclose Maven Catheter |
| Seqirus USA INC | $15.53 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.